Literature DB >> 35763107

Novel insights into roles of N6-methyladenosine reader YTHDF2 in cancer progression.

Rui Liu1, Yachun Jia1, Guangyao Kong2, Aili He3,4.   

Abstract

N6-methyladenosine (m6A) is the most abundant RNA modification. M6A RNA methylation is reversible: m6A is installed by "writers", removed by "erasers", and recognized by "readers". Readers are executors to regulate RNA metabolism by recognizing specific m6A sites, including RNA splicing, export, translation and decay. YTHDF2 is the first identified m6A reader protein. YTHDF2 interacts with m6A-containing transcripts to accelerate the degradation process and regulate various biological processes, such as viral infection, stem cell development and cancer progression. Although there are some reviews about m6A modification in physiological and pathological processes, few reviews focus on roles of YTHDF2 in cancers to date. Therefore, in this review, we attempted to systematically summarize m6A reader protein YTHDF2: its structure, mechanisms in regulating RNA metabolism, roles in cancer progression and potential application for cancer treatment, which might inspire new ideas for m6A research in cancers and provide novel insights into cancer treatment.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cancer progression; Cancer therapy; YTHDF2; m6A modification

Mesh:

Substances:

Year:  2022        PMID: 35763107     DOI: 10.1007/s00432-022-04134-7

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.322


  100 in total

1.  Localization of N6-methyladenosine in the Rous sarcoma virus genome.

Authors:  K Beemon; J Keith
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

2.  YTH domain family 2 orchestrates epithelial-mesenchymal transition/proliferation dichotomy in pancreatic cancer cells.

Authors:  Jixiang Chen; Yaocheng Sun; Xiao Xu; Dawei Wang; Junbo He; Hailang Zhou; Ying Lu; Jian Zeng; Fengyi Du; Aihua Gong; Min Xu
Journal:  Cell Cycle       Date:  2017-11-14       Impact factor: 4.534

3.  The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.

Authors:  Frederick R Appelbaum; Kenneth J Kopecky; Martin S Tallman; Marilyn L Slovak; Holly M Gundacker; Haesook T Kim; Gordon W Dewald; Hagop M Kantarjian; Sherry R Pierce; Elihu H Estey
Journal:  Br J Haematol       Date:  2006-08-25       Impact factor: 6.998

4.  N6-methyladenosine residues in an intron-specific region of prolactin pre-mRNA.

Authors:  S M Carroll; P Narayan; F M Rottman
Journal:  Mol Cell Biol       Date:  1990-09       Impact factor: 4.272

5.  N6-methyladenosine marks primary microRNAs for processing.

Authors:  Claudio R Alarcón; Hyeseung Lee; Hani Goodarzi; Nils Halberg; Sohail F Tavazoie
Journal:  Nature       Date:  2015-03-18       Impact factor: 49.962

6.  Modified nucleosides and bizarre 5'-termini in mouse myeloma mRNA.

Authors:  J M Adams; S Cory
Journal:  Nature       Date:  1975-05-01       Impact factor: 49.962

7.  Targeted mRNA degradation by deadenylation-independent decapping.

Authors:  Gwenael Badis; Cosmin Saveanu; Micheline Fromont-Racine; Alain Jacquier
Journal:  Mol Cell       Date:  2004-07-02       Impact factor: 17.970

Review 8.  An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1.

Authors:  Sayer Al-Harbi; Mahmoud Aljurf; Mohamad Mohty; Fahad Almohareb; Syed Osman Ali Ahmed
Journal:  Blood Adv       Date:  2020-01-14

9.  MODOMICS: a database of RNA modification pathways. 2017 update.

Authors:  Pietro Boccaletto; Magdalena A Machnicka; Elzbieta Purta; Pawel Piatkowski; Blazej Baginski; Tomasz K Wirecki; Valérie de Crécy-Lagard; Robert Ross; Patrick A Limbach; Annika Kotter; Mark Helm; Janusz M Bujnicki
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

10.  YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma.

Authors:  Rui-Chao Chai; Yu-Zhou Chang; Xin Chang; Bo Pang; Song Yuan An; Ke-Nan Zhang; Yuan-Hao Chang; Tao Jiang; Yong-Zhi Wang
Journal:  J Hematol Oncol       Date:  2021-07-10       Impact factor: 17.388

View more
  1 in total

Review 1.  Crosstalk among N6-methyladenosine modification and RNAs in central nervous system injuries.

Authors:  Mi Tian; Lei Mao; Li Zhang
Journal:  Front Cell Neurosci       Date:  2022-09-29       Impact factor: 6.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.